NTBI in patients with hereditary hemochromatosis (HHC) and end-stage renal disease (ESRD)
| Patient group . | Controls* . | HHC† . | ESRD‡ . |
|---|---|---|---|
| Total number tested | 46 | 32 | 68 |
| Number NTBI positives | 22-153 | 22 | 15 |
| Percentage NTBI positives | 4.3 | 69 | 22 |
| Average [NTBI] (μmol/L) | 0.8 | 11.9 | 3.8 |
| Range [NTBI] (μmol/L) | 0.3-1.2 | 4.0-16.3 | 0.1-13.5 |
| Patient group . | Controls* . | HHC† . | ESRD‡ . |
|---|---|---|---|
| Total number tested | 46 | 32 | 68 |
| Number NTBI positives | 22-153 | 22 | 15 |
| Percentage NTBI positives | 4.3 | 69 | 22 |
| Average [NTBI] (μmol/L) | 0.8 | 11.9 | 3.8 |
| Range [NTBI] (μmol/L) | 0.3-1.2 | 4.0-16.3 | 0.1-13.5 |
The samples were tested by the modified procedure for low transferrin saturation sera.
The controls were chosen randomly from samples taken at a local clinic for measurements of transferrin saturation and/or serum ferritin. None of them was suspected of having iron overload.
HHC serum samples were obtained from Prof P. Brissot, Clinique des maladies du foie, CHU Pontchaillou-Rennes, France.
Patients had not received IV iron for at least 7 days before being tested.
One of these patients had taken iron supplement tablets several hours before being tested.